Influence of virus strain, challenge dose, and time of therapy initiation on the in vivo influenza inhibitory effects of RWJ-270201
- 6 July 2001
- journal article
- Published by Elsevier in Antiviral Research
- Vol. 51 (3) , 179-187
- https://doi.org/10.1016/s0166-3542(01)00149-8
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Comparison of the Anti-Influenza Virus Activity of RWJ-270201 with Those of Oseltamivir and ZanamivirAntimicrobial Agents and Chemotherapy, 2001
- In Vivo Influenza Virus-Inhibitory Effects of the Cyclopentane Neuraminidase Inhibitor RWJ-270201Antimicrobial Agents and Chemotherapy, 2001
- Cyclopentane Neuraminidase Inhibitors with Potent In Vitro Anti-Influenza Virus ActivitiesAntimicrobial Agents and Chemotherapy, 2001
- BCX-1812 (RWJ-270201): Discovery of a Novel, Highly Potent, Orally Active, and Selective Influenza Neuraminidase Inhibitor through Structure-Based Drug DesignJournal of Medicinal Chemistry, 2000
- Inhibition of influenza virus infections in mice by GS4104, an orally effective influenza virus neuraminidase inhibitorAntiviral Research, 1998
- Utilization of pulse oximetry for the study of the inhibitory effects of antiviral agents on influenza virus in miceAntimicrobial Agents and Chemotherapy, 1992
- Effect of selenazofurin on influenza A and B virus infections of miceAntiviral Research, 1986